If you are an investor like Wall Street, you may be concerned that Wall Street is on the verge of collapse. As the market fluctuates and more shares are traded on the nosebleeds, there are signs that another catastrophe is imminent.
Although such failures are imminent, it is important for long-term investors to look for strong businesses with strong trademark authority and to maintain resilience records in a variety of economic environments.
If you are trying to prepare your portfolio for further destruction, here are two stocks that can make a strong performance even if the market turns out to be bad.
Mega Cap technology giant Letter (NASDAQ: GOOGL) (NASDAQ: GOOG) Amazing stock price discovery continues history – growing by more than 60 percent last year alone. And depending on analysts’ price targets, the stock still has about 8% to 12%.
The company has proven its resilience in various market areas and has continued to grow continuously at the top and bottom throughout the epidemic. In 2020, revenues increased by 13 percent and net revenues grew by 17%.
Fidel is known for a variety of businesses, including YouTube, Google Cloud, and Google Search. The last of these, the world’s most used search engine with more than 92% market share, continues to account for most of FAANG’s revenues.
In Q1 2021 – the most recently reported quarter – total revenues increased by 34% year-over-year, and net income increased by 162%. At the time, Fidel had a total revenue of $ 55.3 billion, an estimated $ 38.2 billion from Google services, including Google search and YouTube ads. Google Cloud is also contributing to the company’s overall growth: it generated more than $ 4 billion in the first quarter, up from $ 2.7 billion a year earlier.
The spell is also strong in terms of fluidity with short-term obligations. Compared to the current debt of only $ 55.5 billion, it closed the first quarter with a total of $ 135.1 billion in cash, cash equivalents and securities.
From the basic strength of the business to the unparalleled brand authority, to the stable level of development, to the strong financial position, there are many things to love about the letter. Long-term investors can still drink a lot of untapped potential juice from this huge growth stock.
2. Johnson and Johnson
While Johnson and Johnson (NYSE: JNJ) Lightning’s fast-paced profit last year: In addition, this proven and proven stockpile has a lot to offer to long-term investors with a consistent portfolio growth. The company is well-known for its prescription drugs, medical devices and consumer products.
After the stock market crash in March 2020, Johnson & Johnson’s rapid return after a sharp fall in stock prices underscores the core strength of the business. Shares have gained 11% in the last 12 months, and will return 33 percent after five years.
It should be noted that these five-year findings are still far below the S&P 500’s, and are generally 100% shy. Although Johnson and Johnson are able to provide stable – albeit modest – portfolio incentives through affordable price growth, I would argue that the core strength of the business is in conjunction with the company’s unique profit margins that will provide the most compelling incentives in the long run. Buy investors in time.
Here’s what low-risk investors want to hear: Johnson and Johnson are on the relatively short-lived Kingings list – companies have been growing their profits for 50 years or more in a row. New Brunswick, an engine-based company, has increased its profit margin for 59 years each year. It produces a strong 2.5% of current stock prices.
Linn In the first quarter of 2021, sales of Johnson & Johnson increased by about 8 percent year-over-year, and adjusted earnings per share (EPS) increased by approximately 13%. Sales from Lystraine and Johnson’s baby products, as well as prescription drugs for the treatment of psoriasis and multiple myocardial infarction, were important sources of growth for the company over the quarter.
Johnson and Johnson expect to report more than 9% of sales growth by fiscal year 2021. Investors should keep an eye on the numbers as the company announces earnings in the second quarter on Wednesday.
Although this is not a spontaneous acquisition of Johnson and Johnson shares, investors should not underestimate the potential for future revenue growth from the single-dose COVID-19 vaccine currently being distributed. Non-profit foundation. Johnson and Johnson have signed another ሚሊዮን 40 million deal with the European Union, Reuters reports. The management recently released new information about the vaccine, which produces “strong, consistent activity against the rapidly expanding Delta variant and other widespread SARS-CoV-2 viruses.”
For the time being, investors have many other compelling reasons to buy Johnson and Johnson shares. The company, which has been around for 150 years, has a reputation for excelling products and brands that will continue to generate strong sales and revenue growth. These include drugs that target areas ranging from oncology to infectious diseases to immunology. Giant consumer health brands such as OGX, Aveeno, Tylenol and Johnson; And medical equipment is widely used, from reconstruction to sports injury treatment. In the first quarter alone, Johnson & Johnson’s pharmaceutical department saw a 7% increase in sales, while the pharmaceutical division saw a jump of about 9%.
As one of the world’s largest pharmaceutical companies, Johnson & Johnson is the smartest stock you can buy and hold in your life, from its profits to its impressive business record.
This article represents the author’s opinion, which may not agree with the “Official” recommendation of the Motel Ful Premium Consulting Service. We are Motoli! Asking for an investment research paper – even our own – will help us all think about investment and make decisions that will help us become smarter, happier and richer.